Bill Snyder

October 7, 2021

Nominations sought for VUSM Research Staff Awards

By Bill Snyder
October 5, 2021

AstraZeneca seeks emergency approval for COVID-19 antibodies isolated at VUMC

Biopharmaceutical company AstraZeneca has requested emergency use authorization (EUA) from the U.S. Food and Drug Administration for a long-acting antibody combination originally developed at Vanderbilt University Medical Center to protect against COVID-19.

By Bill Snyder
October 1, 2021

VUMC research contributed to first COVID-19 pill now under review

Vanderbilt research helped allow pharmaceutical giant Merck & Co. to authorization for the first oral antiviral pill to treat COVID-19.

By Bill Snyder
September 29, 2021

Neurotransmitter transporters expert Amara set for Oct. 7 Discovery Lecture

Susan Amara, PhD, scientific director of the Intramural Research Program at the NIMH and an expert on the biology of neurotransmitter transporters, will deliver Vanderbilt’s next Discovery Lecture via Zoom at 4 p.m., Thursday, Oct. 7.

By Bill Snyder
September 22, 2021

“Ultra-potent” antibody against COVID-19 variants isolated at VUMC

A technology developed at Vanderbilt has led to the discovery of an “ultra-potent” monoclonal antibody against multiple variants of SARS-CoV-2, the virus responsible for COVID-19, including the delta variant.

By Bill Snyder
September 16, 2021

VUMC team to test personalized acute heart failure treatment

Researchers at Vanderbilt have been awarded a five-year, $4 million federal grant to test whether a personalized medicine strategy will improve outcomes for patients hospitalized with acute heart failure.

By Bill Snyder
September 16, 2021

Chung receives early investigator award from ASCPT

Vanderbilt's Cecilia Chung, MD, MPH, has received the 2022 Leon I. Goldberg Early Investigator Award from the American Society of Clinical Pharmacology and Therapeutics (ASCPT).
By Bill Snyder
September 16, 2021

‘Pre-conditioning’ restores immune tolerance

A treatment targeting T-cell metabolism could reinvigorate immune tolerance mechanisms to combat autoimmune disease and transplant rejection, Vanderbilt researchers discovered.
By Bill Snyder
September 8, 2021

VUMC antibodies help neutralize two deadly viruses: study

Vanderbilt researchers have isolated monoclonal antibodies that prevent severe illness and death caused by two emerging and deadly viruses called Nipah and Hendra.
By Bill Snyder
September 2, 2021

Discovery offers insight for development of cancer therapies targeting mutant p53

Vanderbilt researchers have discovered that aneuploidy (an abnormal number of chromosomes) drives malignant phenotypes in cells expressing mutant p53, a tumor suppressor protein that is mutated in more than half of all human cancers.
By Bill Snyder
September 2, 2021

A leading authority in ICU-related depression and PTSD, Jim Jackson’s skills have proven especially critical to helping patients during the pandemic

"The last year has been so traumatizing and hard, but to use the skills and knowledge that we have been developing to good effect in the service of others during this difficult season has been meaningful.”
By Bill Snyder
August 20, 2021

COVID-19 antibody ‘cocktail’ discovered at VUMC protects chronically ill: study

A monoclonal antibody cocktail against the COVID-19 virus discovered at Vanderbilt University Medical Center and developed by AstraZeneca reduced the risk of symptoms in a study of immunocompromised and chronically ill adults later exposed to the virus by 77%, the company announced today.
By Bill Snyder
1 … 27 28 29 30 31 … 115